ES2177811T3 - Uso de nitroflavonoides para el tratamiento de la ansiedad. - Google Patents

Uso de nitroflavonoides para el tratamiento de la ansiedad.

Info

Publication number
ES2177811T3
ES2177811T3 ES96935000T ES96935000T ES2177811T3 ES 2177811 T3 ES2177811 T3 ES 2177811T3 ES 96935000 T ES96935000 T ES 96935000T ES 96935000 T ES96935000 T ES 96935000T ES 2177811 T3 ES2177811 T3 ES 2177811T3
Authority
ES
Spain
Prior art keywords
formula
anxiety
nitroflavonoids
treatment
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96935000T
Other languages
English (en)
Inventor
Alejandro Constantino Paladini
Jorge Horacio Medina
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Strathclyde
Original Assignee
University of Strathclyde
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Strathclyde filed Critical University of Strathclyde
Application granted granted Critical
Publication of ES2177811T3 publication Critical patent/ES2177811T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/32—2,3-Dihydro derivatives, e.g. flavanones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

SE DESCRIBEN PROCEDIMIENTOS PARA TRATAR LA ANSIEDAD CON COMPUESTOS FLAVONOIDES SEGUN LA FORMULA (I) Y DIMEROS DE LOS MISMOS, COMPUESTOS DE FORMULA (I) Y DIMEROS DE LOS MISMOS, EL USO DE COMPUESTOS DE FORMULA (I) Y FORMULADOS FARMACEUTICOS QUE INCLUYEN FLAVONOIDES DE FORMULA (I) Y DIMEROS DE LOS MISMOS.
ES96935000T 1995-10-17 1996-10-16 Uso de nitroflavonoides para el tratamiento de la ansiedad. Expired - Lifetime ES2177811T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9521184.3A GB9521184D0 (en) 1995-10-17 1995-10-17 Flavonoids

Publications (1)

Publication Number Publication Date
ES2177811T3 true ES2177811T3 (es) 2002-12-16

Family

ID=10782385

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96935000T Expired - Lifetime ES2177811T3 (es) 1995-10-17 1996-10-16 Uso de nitroflavonoides para el tratamiento de la ansiedad.

Country Status (9)

Country Link
US (1) US6080780A (es)
EP (1) EP0857066B1 (es)
JP (1) JP4745468B2 (es)
AU (1) AU7310896A (es)
DE (1) DE69621447T2 (es)
ES (1) ES2177811T3 (es)
GB (1) GB9521184D0 (es)
WO (1) WO1997014414A1 (es)
ZA (1) ZA968773B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9707013D0 (en) * 1997-04-07 1997-05-28 Univ Strathclyde Halo and/or nitro-substituted flavonoids
US7183314B1 (en) 2000-07-21 2007-02-27 Naturon Limited Compound for treatment of anxiety and methods of preparation and use thereof
RU2209062C1 (ru) * 2002-03-19 2003-07-27 Институт физиологии им. И.П.Павлова РАН Вещество, обладающее седативным действием
GB0216371D0 (en) * 2002-07-13 2002-08-21 Rowett Res Inst The Compounds
US20050080024A1 (en) * 2002-08-15 2005-04-14 Joseph Tucker Nitric oxide donating derivatives for the treatment of cardiovascular disorders
US20050080021A1 (en) * 2002-08-15 2005-04-14 Joseph Tucker Nitric oxide donating derivatives of stilbenes, polyphenols and flavonoids for the treatment of cardiovascular disorders
US20040033480A1 (en) * 2002-08-15 2004-02-19 Wong Norman C.W. Use of resveratrol to regulate expression of apolipoprotein A1
US6740677B2 (en) 2002-08-19 2004-05-25 Hong Xue Methods of treating benzodiazepine site (BZD-S) associated syndromes using 2′ hydroxyflavonoids
US20090221568A1 (en) * 2005-11-04 2009-09-03 Jared Shaw Synthesis of Inhibitors of FtsZ
EP2478901A3 (en) * 2007-02-14 2012-11-14 Mars Incorporated Neurogenic compounds
GB201017315D0 (en) 2010-10-13 2010-11-24 Antoxis Ltd Compound
US10123991B2 (en) 2015-05-15 2018-11-13 Global Biolife Inc. Electrophilically enhanced phenolic compounds for treating inflammatory related diseases and disorders
KR20190022085A (ko) * 2017-08-25 2019-03-06 건국대학교 글로컬산학협력단 타마리세틴을 유효성분으로 포함하는 패혈증 또는 패혈증성 쇼크의 예방 또는 치료용 약학적 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9317071D0 (en) * 1993-08-17 1993-09-29 Univ Strathclyde Flavonoids

Also Published As

Publication number Publication date
EP0857066A1 (en) 1998-08-12
GB9521184D0 (en) 1995-12-20
WO1997014414A1 (en) 1997-04-24
JP4745468B2 (ja) 2011-08-10
US6080780A (en) 2000-06-27
AU7310896A (en) 1997-05-07
EP0857066B1 (en) 2002-05-29
DE69621447D1 (de) 2002-07-04
JP2000505055A (ja) 2000-04-25
ZA968773B (en) 1997-05-27
DE69621447T2 (de) 2003-05-08

Similar Documents

Publication Publication Date Title
ECSP055609A (es) "Uso de inhibidores de la IkB-quinasa para el tratamiento del dolor"
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
ES2100151T3 (es) Nuevos derivados de benzopirano, procedimientos para su preparacion y su uso y composiciones que contienen los compuestos.
ES2186015T3 (es) Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol.
ES2195970T3 (es) L-ribavirina y usos de la misma.
AR005703A1 (es) Oxazolidinonas sustituidas, procedimiento para su preparacion, uso de las mismas para preparar medicamentos y medicamentos que las contienen
ES2085876T3 (es) Derivado de bifenilmetano, su utilizacion y composiciones farmacologicas que contienen el mismo.
AR010062A1 (es) Nuevos benzamidaldehidos y su utilizacion
ES2172670T3 (es) Pirrolpirimidinas y procedimientos para su preparacion.
AR020020A1 (es) Composicion para el tratamiento de cancer y metodo usando moduladores de transduccion de senal y aceites esenciales de plantas naturales como sinergistas para tratamientos convencionales
AR023727A1 (es) Compuestos empleados en el tratamiento de padecimientos inflamatorios
ECSP034924A (es) Derivados sustituidos del 1-oxa-2,8-daza-espiro[4,5]dec-2-eno
ES2138691T3 (es) Procedimiento para la obtencion de derivados de n-acil-5-fluorocitidina.
ES2058185T3 (es) Derivados de camptotecina y procedimiento para su preparacion.
ES2154674T3 (es) Derivados de 1,5-benzodiacepinas con actividad antagonista o agonista de cck.
ES2186783T3 (es) Derivados de la dolastatina, su preparacion y uso.
ES2177811T3 (es) Uso de nitroflavonoides para el tratamiento de la ansiedad.
IT1285770B1 (it) Composti corticoidei
PA8555501A1 (es) Compuestos de benzimidazol sustituido y su uso para el tratamiento del cancer
ES2187738T3 (es) Derivados de flavonas, su procedimiento de preparacion y los compuestos farmaceuticos que las contienen.
ES2076595T3 (es) Derivados de amidinofenilalanina, procedimiento para su preparacion, su empleo y agentes que los contienen.
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
IS4367A (is) CCK eða gastrín temprandi 5-heterósýklísk-1,5-bensódíazepín
AR001813A1 (es) Derivados de cromona procedimiento para prepararlos y las composiciones farmacéutica que los contienen
MX9302034A (es) Bencidazoles, medicamentos que contienen estos compuestos y procedimientos para su preparacion.